Immunoglobulin (IgG) Replacement Therapy Market Size & Share, by Route of Administration (Intravenous, Subcutaneous); Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease); Distribution Channel (Hospitals, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5635
  • Published Date: Feb 12, 2024
  • Report Format: PDF, PPT

Companies Dominating the Immunoglobulin (IgG) Replacement Therapy Landscape

top-features-companies
    • Boehringer Ingelheim
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Grifols, S.A.
    • Octapharma AG
    • CSL Limited
    • BDI Pharma Inc.
    • China Biologics Products Inc.
    • Abeona Therapeutics
    • Baxter International Inc.
    • Kedrion Biopharma
    • LFB Group

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Boehringer Ingelheim declared that it has begun the Phase 1 research (NCT05658107) to evaluate the safety, tolerability, and pharmacokinetics of BI 765423, its first-in-class IL-11 inhibitor antibody, in healthy volunteers. Boehringer Ingelheim is already a world leader in the management of pulmonary fibrosis, and the company's long-term dedication to treating fibrotic disease across therapeutic domains is demonstrated by the start of the anti-IL-11 treatment's clinical development.
  • Leading manufacturer of plasma medications, Grifols, has begun selling its 20% subcutaneous immunoglobulin, XEMBIFY®, in Spain. Primary immunodeficiencies (PID) and some secondary immunodeficiencies (SID), the prevalence of which is predicted to rise sharply in the next several years, are the conditions for which this plasma medication is advised.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5635
  • Published Date: Feb 12, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of CIDP and PIDs globally, increased utilization of immunoglobulin replacement therapy in Kawasaki illness, and increased launches of innovative therapies by key manufacturers are the major factors driving the growth of the immunoglobulin (IgG) replacement therapy market.

The market size of Immunoglobulin (IgG) Replacement Therapy is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2024-2036.

The major players in the market are Boehringer Ingelheim, Grifols, S.A., Octapharma AG, CSL Limited, BDI Pharma Inc., China Biologics Products Inc., Abeona Therapeutics, Baxter International Inc., Kedrion Biopharma, LFB Group, Takeda Pharmaceutical Company Limited, Alexion Pharma LLC., Daiichi Sankyo Co Ltd., CSL Behring Co. Ltd., Teijin Pharma Co., Ltd. and others.

The intravenous segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying